Continuous diphenhydramine infusion and imatinib for KIT-D816V-negative mast cell activation syndrome: a case report
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We present the first full case report of the treatment of mast cell activation syndrome with continuous diphenhydramine infusion, which resulted in the improvement of anaphylactic reactions and a decrease in hospital readmission. Furthermore, the patient received imatinib in the absence of the KIT-D816V mutation, which led to further improvement of quality of life. Currently, we are trying to wean this patient off diphenhydramine; if successful, this attempt will represent the first reported case. CASE PRESENTATION: An 18-year-old white girl presented with a flare of mast cell activation syndrome and received epinephrine and steroids. She had failed multiple previous therapies, and her quality of life was affected due to two to three flares/week. She was started on continuous diphenhydramine infusion and imatinib, which led to a decrease in hospital admissions and marked improvement in her quality of life. CONCLUSIONS: Continuous diphenhydramine infusion can provide promising outcomes following the failure of intermittent antihistamine dosing in patients with severe mast cell activation syndrome. Initiating continuous diphenhydramine infusion may be helpful in an intensive care setting when the patient is particularly prone to anaphylaxis and/or the resources needed to manage anaphylaxis are not available outside the intensive care unit. Furthermore, imatinib provides benefits in KIT-D816V-negative mast cell disorders due to other unknown mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In addition, the wrong diagnosis may lead to an inappropriate use of certain pharmacologic agents. 136”
From Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review (2021) · cites this paper as [136]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longley, B. J., Metcalfe, D. D., Tharp, M., Wang, X., Tyrrell, L., Lu, S.-Z., Heitjan, D., & Ma, Y. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.4.1609 · Cited by 552
Development of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis
Schwartz, L. B., Bradford, T. R., Rouse, C., Irani, A.-M., Rasp, G., Van Der Zwan, J. K., & Van Der Linden, P.-W. G. (1994) · Journal of Clinical Immunology · doi:10.1007/bf01533368 · Cited by 263
Significance of systemic mast cell disease with associated hematologic disorders
Travis, W. D., Li, C.-Y., Yam, L. T., Bergstralh, E. J., & Swee, R. G. (1988) · Cancer · doi:10.1002/1097-0142(19880901)62:5<965::aid-cncr2820620520>3.0.co;2-m · Cited by 225
Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis
Ustun, C., Reiter, A., Scott, B. L., Nakamura, R., Damaj, G., Kreil, S., Shanley, R., Hogan, W. J., Perales, M.-A., Shore, T., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.2018 · Cited by 190
Mast Cell Leukemia: Report of a Case and Review of the Literature
TRAVIS, W. D., LI, C.-Y., HOAGLAND, H. C., TRAVIS, L. B., & BANKS, P. M. (1986) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)62636-6 · Cited by 160
Molderings, G. J., Brettner, S., Homann, J., & Afrin, L. B. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-10 · Cited by 149 · cited 1×
“To avoid the side effects from steroids, steroid-sparing agents, such as azathioprine, or other immunosuppressive therapies, such as cyclosporine and methotrexate, should be considered [15].”
BackgroundImatinib mesylate in the treatment of systemic mastocytosis: A phase II trial
Droogendijk, H. J., Kluin‐Nelemans, H. J. C., van Doormaal, J. J., Oranje, A. P., van de Loosdrecht, A. A., & van Daele, P. L. A. (2006) · Cancer · doi:10.1002/cncr.21996 · Cited by 147
Urticaria pigmentosa; a report of a case with autopsy.
Jm, E. (1949) · PubMed · Cited by 147
Systemic mastocytosis: Extracutaneous manifestations
Brunning, R. D., Parkin, J. L., McKenna, R. W., Risdall, R., & Rosai, J. (1983) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198307000-00005 · Cited by 142
Mast cells and canine mast cell tumours. A review
Misdorp, W. (2004) · Veterinary Quarterly · doi:10.1080/01652176.2004.9695178 · Cited by 128
Cited by
Gülen, T., Akin, C., Bonadonna, P., Siebenhaar, F., Broesby-Olsen, S., Brockow, K., Niedoszytko, M., Nedoszytko, B., Oude Elberink, H. N. G., Butterfield, J. H., et al. (2021) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2021.06.011 · Cited by 83
“In addition, the wrong diagnosis may lead to an inappropriate use of certain pharmacologic agents.(136)”
Background
Metadata
- Authors
- Malik, F., Ali, N., Jafri, S. I. M., Ghani, A., Hamid, M., Boigon, M., & Fidler, C.
- Affiliations
- Abington Memorial Hospital (US)
- Thomas Jefferson University Hospital (US)
- Corresponding author
- Malik, Faizan
- Venue
- Journal of Medical Case Reports
- Published
- 2017-04-24
- Volume
- 11
- Issue
- 1
- Pages
- 119-119
- ISSN
- 1752-1947 (ISSN-L)
- PMC
- PMC5402659
- OpenAlex
- W2609982265
- Cited by
- 3
- References
- 24
- Citations by year
- 2024: 1 · 2021: 1 · 2019: 1
- FWCI
- 0.12
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Journal of Medical Case Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Keywords
- mast cell activation syndrome, imatinib, anaphylaxis, antihistamine therapy, KIT mutations, hospital readmission, quality of life
- MeSH terms
- Imatinib Mesylate, Adolescent, Diphenhydramine, Female, Histamine H1 Antagonists, Humans, Infusions, Parenteral, Mastocytosis, Quality of Life, Treatment Outcome, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Continuous diphenhydramine infusion and imatinib for KIT-D816V-negative mast cell activation syndrome: a case report. https://app.cochat.ai/papers/10.1186/s13256-017-1278-3
- The paper
- Malik, F., Ali, N., Jafri, S. I. M., Ghani, A., Hamid, M., Boigon, M., & Fidler, C. (2017). Continuous diphenhydramine infusion and imatinib for KIT-D816V-negative mast cell activation syndrome: a case report. Journal of Medical Case Reports. https://doi.org/10.1186/s13256-017-1278-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.